ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

ClinicalTrials.gov ID: NCT00004255

Public ClinicalTrials.gov record NCT00004255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia

Study identification

NCT ID
NCT00004255
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Chimeric Therapies
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

  • allogeneic bone marrow transplantation Procedure
  • anti-thymocyte globulin Biological
  • cyclophosphamide Drug
  • filgrastim Biological
  • fludarabine phosphate Drug
  • in vitro-treated bone marrow transplantation Procedure
  • methylprednisolone Drug
  • radiation therapy Radiation
  • tacrolimus Drug

Procedure · Biological · Drug + 1 more

Eligibility (public fields only)

Age range
12 Years to 50 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2000
Primary completion
Not listed
Completion
Apr 30, 2003
Last update posted
Jul 9, 2013

2000 – 2003

United States locations

U.S. sites
15
U.S. states
13
U.S. cities
15
Facility City State ZIP Site status
University of California San Diego Cancer Center La Jolla California 92093-0658
Presbyterian-St Luke's Medical Center Denver Colorado 80218
Lombardi Cancer Center Washington D.C. District of Columbia 20007
Shands Hospital and Clinics, University of Florida Gainesville Florida 32610-100277
Indiana Blood and Marrow Transplantation Indianapolis Indiana 46202
James Graham Brown Cancer Center Louisville Kentucky 40202
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201-1379
University of Rochester Cancer Center Rochester New York 14642
New York Medical College Valhalla New York 10595
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73190
Oregon Cancer Center Portland Oregon 97201-3098
Hahnemann University Hospital Philadelphia Pennsylvania 19102-1192
University of Texas - MD Anderson Cancer Center Houston Texas 77030-4009
South Texas Cancer Institute San Antonio Texas 78229
Massey Cancer Center Richmond Virginia 23298-0037

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00004255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 9, 2013 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00004255 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →